Glaucoma Clinical Trial
Official title:
Effect of Brimonidine 0.15% on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Tension Glaucoma
The investigators have completed a study in which the investigators examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with Normal Tension Glaucoma (NTG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vasculature. In a healthy retina, the vasculature adapts by dilating and constricting in order to maintain a steady blood flow rate. In an eye with NTG, this often does not occur. Upon analysis at the completion of the study , the investigators found that the patients who had been taking Alphagan (brimonidine) during the study did not exhibit the blood flow increases typical of NTG while lying down; instead, they maintained a steady blood flow rate as did the group of healthy control subjects. The investigators primary objective is to now demonstrate in a prospective study that Alphagan can restore retinal vascular autoregulatory function in patients with NTG who do not autoregulate. The investigators will also determine the effect of Alphagan treatment on the patients' ability to detect motion.
This is a prospective, nonrandomized clinical trial of POAG patients with a history of
untreated IOP <22 mm Hg.
RETINAL VASCULAR AUTOREGULATION TESTING PROTOCOL:
At approximately 10 AM, we allowed subjects to sit for 15 minutes and then measured blood
pressure and heart rate using a Keller Vital Signs Monitor (Keller Medical Specialties,
Antioch, Illinois, USA). We measured seated IOP in both eyes using Goldmann applanation
tonometry (Haag Streit USA, Mason, Ohio, USA) and 1 eye was dilated with tropicamide 1%.
Baseline seated ocular perfusion pressure (OPP) was estimated using the standard formula:
OPP=2/3 MAP - IOP, where MAP refers to mean arterial pressure. The factor of two-thirds
adjusts for the decline in blood pressure between the brachial and ophthalmic artery with
the subject sitting. We used the Canon CLBF 100 Laser Blood Flowmeter (Canon Inc, Tokyo,
Japan) to measure baseline retinal arterial blood column diameter and centerline blood
speed, which allows for automatic calculation of the blood flow rate. We chose a site along
either the inferior temporal retinal artery or the superior temporal retinal artery adjacent
to the optic disc for baseline measurements. Following the baseline measurements, the
subjects assumed a posture typically used for face-on x-rays, reclining on their right side
with their head supported by a foam wedge making a 24-degree angle from the horizontal.
Subjects reclined for 30 minutes while brachial blood pressure and heart rate were
automatically measured at 5-minute intervals. Laser Doppler blood flow measurements were
obtained from the same arterial site that was used at baseline after approximately 15 and 30
minutes of reclining. Immediately following the 30-minute laser Doppler measurement, with
the subject still reclining, we used the Perkins handheld applanation tonometry (Haag Streit
USA) to remeasure IOP in the eye undergoing hemodynamic testing. In the reclined position,
OPP was estimated using the following formula: OPPreclining = MAPreclining - IOPreclining,
where MAPreclining is the mean brachial artery blood pressure measured in the left arm with
the subject reclining on the right side. Subsequently, blood pressure, heart rate, and laser
Doppler measurements were repeated after the subjects were reseated for 15 minutes.
Only patients who exhibited retinal vascular dysregulation continued in the study. We
defined retinal vascular dysregulation based on the percentage change between the retinal
blood flow measured while reclining for 30 minutes and the baseline seated measures.
Previously, we found that healthy subjects exhibited a +6.5% +/- 12% blood flow change
induced by 30 minutes of reclining. Thus, we defined the normal range of blood flow
autoregulation as within 2 standard deviations of the mean percentage change found in this
group, or -17.5% to +30.5%. Patients who exhibited retinal vascular dysregulation began an
8-week course of brimonidine 0.15% 3 times a day in both eyes. Subsequently, they returned
at 10 AM and repeated the testing protocol described above. We obtained retinal hemodynamic
measurements at the same retinal arterial site used during the initial visit. Each patient
also underwent visual function testing in the eye that had hemodynamic studies both before
and after 8-week treatment with brimonidine 0.15%.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A |